Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PFE heads into its October 27 quarterly print having lost 4.2% on the week, trading at $27.50, with the insider buying cluster documented a week ago still the clearest signal of conviction around the stock.
The analyst desk has turned incrementally more constructive since that note. Scotiabank raised its target to $33 from $30 on October 6, maintaining its Sector Outperform rating. That follows HSBC lifting its target to $30 from $28 in September. The direction of recent moves contrasts with a wave of cuts through July, when JPMorgan, BofA, BMO Capital and Guggenheim all trimmed targets while keeping their ratings in place. The mean target across the Street is $28.91, a modest premium to the current price. Bulls point to $60 billion in annual sales, a diversified international revenue base, and a forward EPS trajectory that ORTEX factor scores place in the 88th percentile year-on-year. Bears worry about gross-to-net adjustments on Vyndaqel and Ibrance compressing reported revenue, and the broader vulnerability of a franchise still reliant on legacy prescription drugs and vaccines. The stock's EV/EBITDA of 8.6x and P/E of 9.4x are both drifting lower over the past 30 days, consistent with a market that is not yet willing to re-rate on the bull case alone.
Short positioning remains a non-story, and that has not changed from the prior week. Short interest is 2.6% of the free float, down roughly 2.6% over the week to approximately 148 million shares. The borrow market is as loose as it gets: availability is effectively uncapped, with nearly 4.75 billion shares available to lend against current short positions. Cost to borrow is 0.40%, up around 9% on the week but from an already negligible base. The ORTEX short score is 35.2, stable over the past two weeks. None of this points to any pressure building from the short side.
Options positioning is similarly calm. The put/call ratio is 0.75, just above its 20-day average of 0.745, with a z-score of 0.33. The 52-week range runs from 0.64 to 0.94, placing the current reading in the middle of the band. There is no sign of the defensive hedging that was visible in September, when the ratio was running above 0.80. The tone from options traders is broadly neutral ahead of earnings.
The insider buying cluster from August remains the most differentiated piece of data around this stock. CEO Albert Bourla's $1 million open-market purchase on August 12, combined with two board members buying roughly $960,000 to $999,000 each on August 5, produced a 90-day net insider position of 111,585 shares worth approximately $2.9 million. None of those purchases were under a 10b5-1 plan. The stock has moved from around $25.50 at the time of those buys to $27.50 today, a gain of roughly 8%, though this week's decline has erased some of that progress. The alt data layer adds one factual note: Medicaid units reimbursed for Pfizer drugs were down 17% year-on-year in Q1 2026, and Medicaid prescriptions fell 21% over the same period. Neither dataset has been measured to lead Pfizer's reported financials, so neither can be read as pointing toward or away from the upcoming print.
Earnings on October 27 are the obvious next event. The two most recent prior prints produced a 3.1% one-day gain and a 1.9% one-day gain respectively. The question for this print is whether the Street's cautious re-rating through the summer has set a low enough bar, and whether the gross-to-net headwinds the bears have flagged are already in consensus numbers.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
